During the initial evaluation of breast neoplasia, it is routinely recommended to determine the expression of estrogen receptors (ER) and progesterone receptors (PR) by tumor cells, as well as to assess the overexpression of human epidermal growth factor 2 (HER2) receptors. Here, ESR1 is linked to neoplasm.